BAM
IOVA icon

Blueshift Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Blueshift Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,209
Closed -$141K – 654
2026
Q1 		$141K Buy
+40,209
New +$129K 0.04% 465
2025
Q3 		– Sell
-21,991
Closed -$37.8K – 537
2025
Q2 		$37.8K Buy
+21,991
New +$54.7K 0.01% 428
2024
Q3 		– Sell
-15,831
Closed -$127K – 418
2024
Q2 		$127K Buy
+15,831
New +$170K 0.04% 321
2020
Q1 		– Sell
-11,149
Closed -$309K – 435
2019
Q4 		$309K Buy
+11,149
New +$254K 0.04% 595
2019
Q1 		– Sell
-24,325
Closed -$215K – 824
2018
Q4 		$215K Buy
+24,325
New +$235K 0.04% 561

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Blueshift Asset Management's IOVA Position: Q2 2026 in Review

Blueshift Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 40,209 shares — an estimated $141K sold.

Blueshift Asset Management first reported a position in IOVA in Q4 2018 and held it in 5 quarters. The position peaked at $309K in Q4 2019. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Blueshift Asset Management reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Blueshift Asset Management sold 40,209 Iovance Biotherapeutics shares in Q2 2026, an estimated $141K.
  • Blueshift Asset Management first reported a position in Iovance Biotherapeutics in Q4 2018 and held it in 5 quarters.
  • Blueshift Asset Management's Iovance Biotherapeutics position peaked at $309K in Q4 2019.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Blueshift Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.